Efficacy and safety of lanabecestat for treatment of early and mild Alzheimer disease: The amaranth and daybreak-ALZ randomized clinical trials

You might very well need this, assuming your doctor is up-to-date on stroke research and is creating protocols to prevent your dementia. Also assumes your doctor even knows of your need for this.

Your chances of getting dementia.

1. A documented 33% dementia chance post-stroke from an Australian study?   May 2012.

2. Then this study came out and seems to have a range from 17-66%. December 2013.

3. A 20% chance in this research.   July 2013.

4. Dementia Risk Doubled in Patients Following Stroke September 2018 

5. Parkinson’s Disease May Have Link to Stroke March 2017

 

Efficacy and safety of lanabecestat for treatment of early and mild Alzheimer disease: The amaranth and daybreak-ALZ randomized clinical trials

JAMA — Wessels AM, Tariot PN, Zimmer JA, et al. | February 17, 2020

Advertisement

Researchers investigated whether lanabecestat slows the progression of Alzheimer disease (AD) compared with placebo in patients with early AD (mild cognitive impairment) and mild AD dementia. They performed two multicenter, global, double-blind studies at 257 and 251 centers in 15 and 18 countries or territories, respectively. AMARANTH included 2,218 randomized participants, of whom 539 individuals completed the study. DAYBREAK-ALZ included 1,722 (30.2%) randomized participants, of whom 76 individuals completed the study. In all, the researchers found that although lanabecestat was generally well tolerated, it did not slow cognitive or functional decline in individuals with early or mild AD dementia.

Read the full article on JAMA